Regenxbio Inc. (RGNX)
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
The consensus price target hints at a 333% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
The mean of analysts' price targets for Regenxbio (RGNX) points to a 357.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago.
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030.
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024.
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 234.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Patrick Christmas - CLO Curran Simpson - President and CEO Steve Pakola - CMO Vit Vasista - CFO Conference Call Participants Gena Wang - Barclays Vikram Purohit - Morgan Stanley Paul Choi - Goldman Sachs Annabel Samimy - Stifel C.J. Yeh - Leerink Partners Luca Issi - RBC Brian Skorney - Baird Daniil Gataulin - Chardan Capital Markets Operator Welcome everyone to the Q2 2024 REGENXBIO's Earnings Conference Call.
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $1.66 per share a year ago.
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome. ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data.
